title: Assessment of the effect of esterified propoxylated glycerol (EPG) on the status of fat-soluble vitamins and select water-soluble nutrients following dietary administration to humans for 8 weeks.
abstract: This double-blind, randomized, controlled study assessed the effect of esterified propoxylated glycerol (EPG) on fat-soluble vitamins and select nutrients in human subjects. For 8 weeks, 139 healthy volunteers consumed a core diet providing adequate caloric and nutrient intakes. The diet included items (spread, muffins, cookies, and biscuits) providing EPG (10, 25, and 40 g/day) vs. margarine alone (control). EPG did not significantly affect circulating retinol, α-tocopherol, or 25-OH D2, but circulating β-carotene and phylloquinone were lower in the EPG groups, and PIVKA-II levels were higher; 25-OH D3 increased but to a lesser extent than the control. The effect might be related to EPG acting as a lipid "sink" during gastrointestinal transit. No effects were seen in secondary endpoint measures (physical exam, clinical pathology, serum folate, RBC folate, vitamin B12, zinc, iron, calcium, phosphorus, osteocalcin, RBP, intact PTH, PT, PTT, cholesterol, HDL-C, LDL-C, triglycerides). Gastrointestinal adverse events (gas with discharge; diarrhea; oily spotting; oily evacuation; oily stool; liquid stool; soft stool) were reported more frequently by subjects receiving 25 or 40 g/day of EPG. In general, the incidence and duration of these symptoms correlated directly with EPG dietary concentration. The results suggest 10 g/day of EPG was reasonably well tolerated.
authors.affiliation: The University of Chicago Pritzker School of Medicine, 150 E. Huron St., Chicago, IL 60611, United States.
authors.forename: Michael H
authors.initials: MH
authors.lastname: Davidson
authors.affiliation: Best Foods, Division of CPC International, 150 Pierce St., Somerset, NJ 08873, United States. Electronic address: david.bechtel@intertek.com.
authors.forename: David H
authors.initials: DH
authors.lastname: Bechtel
mesh_terms: D015652:25-Hydroxyvitamin D 2 / Q000097:blood; D000293:Adolescent; D000328:Adult; D015415:Biomarkers / Q000097:blood; D002112:Calcifediol / Q000097:blood; D004041:Dietary Fats / Q000008:administration & dosage / Q000009:adverse effects; D004311:Double-Blind Method; D019358:Fat Substitutes / Q000009:adverse effects / Q000494:pharmacology*; D005260:Female; D005989:Glycerides / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011498:Protein Precursors / Q000097:blood; D011516:Prothrombin; D014801:Vitamin A / Q000097:blood; D010837:Vitamin K 1 / Q000097:blood; D014815:Vitamins / Q000097:blood*; D055815:Young Adult; D024502:alpha-Tocopherol / Q000097:blood; D019207:beta Carotene / Q000097:blood
chemical_list: D015415:Biomarkers; D004041:Dietary Fats; D019358:Fat Substitutes; D005989:Glycerides; D011498:Protein Precursors; D014815:Vitamins; D019207:beta Carotene; D014801:Vitamin A; D015652:25-Hydroxyvitamin D 2; C008208:acarboxyprothrombin; D010837:Vitamin K 1; D011516:Prothrombin; D024502:alpha-Tocopherol; D002112:Calcifediol
keywords: Clinical trial; EPG; Esterified propoxylated glycerol; Fat substitute